Participate in a Clinical Trial
Thanks for your involvement!
Clinical trials are a key research tool for advancing medical knowledge and patient care. The knowledge gained will support the treatment we will provide in the years to come. Clinical trials can provide positive impacts for many patients in the future, offering benefits such as new treatments or better drug options. Through rigorous testing, evidence-based trials ensure the solutions are safe and effective before they are used in clinical practice.
Benefits of Clinical Trials
- You may receive a new treatment for a disease or condition before
it is publicly available.
- You play a more active role in your own health care.
- Researchers may provide you with medical care and more frequent
health check-ups as part of your treatment.
- You may have the chance to help others get better treatment for
their health problems in the future.
- You may be able to get information about support groups and
resources.
If you would like to participate in any of our future research studies or would like any information on our current projects, please contact our research department at research@wdmh.on.ca.
Current Clinical Trials
Osteoarthritis MARS - GSK
Osteoarthritis (OA) is a chronic, degenerative
condition that affects both the large and small joints in the body, and is the
most common form of adult arthritis. Both the prevalence and impact of the
disease are steadily increasing worldwide, thus alleviating the chronic pain
associated with OA is currently a major unmet need.
CCL17 is a chemokine that has been recently
identified as a peripheral mediator of inflammatory pain. GSK3858279 is a human
monoclonal antibody that binds to CCL17, and prevents its expression,
potentially helping to alleviate the chronic pain associated with OA.
The purpose of this Phase 2 study is to
investigate the efficacy, safety, PK, TE and dose exposure-efficacy
relationship of GSK3858279, and to provide the data necessary to select the
optimal effective and safe dose(s) of GSK3858279 to be carried forward into
Phase 3 studies in subjects with knee/hip OA.
Atherosclerosis POSEIDON - NovoNordisk
The role of inflammation in atherosclerosis has
been well established, and atherosclerosis is currently considered a hybrid
disease between a metabolic disorder and chronic systemic inflammation. There
is also evidence showing a link between systemic inflammation and risk of
cardiovascular complications. C-reactive protein (CRP) has been shown to be a
reliable measure of underlying systemic inflammation and a strong predictor of
future cardiovascular events.
This study will use a
cross-sectional approach and conduct testing in a large sample of patients to
better understand the prevalence of systemic inflammation in patients with
atherosclerotic cardiovascular disease or heart failure.
EColi - Janssen
This study will assess the safety and efficacy of an E-Coli vaccine, to determine whether the vaccine will help to provide protection from urinary tract infections caused by E-Coli bacteria, and prevent the systemic bacterial infections that can occur.
Primary inclusion criteria: Adults 60+ with a history of UTI within the last 2 years.
OBERON - AstraZeneca
The purpose of this study is to evaluate the efficacy and safety of Tozorakimab, in reducing symptoms and improving quality of life in patients with moderate or severe COPD who are already on optimal therapy.
Primary inclusion criteria: Adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months.
GARDEN-TIMI - Pfizer
The primary purpose of this study is to assess the effect of repeated administration of ponsegromab on frequency, severity, and burden of symptoms, as well as effects on physical limitations in participants with heart failure.
Primary inclusion criteria: Adults aged 18+ with clinical evidence of heart failure, with LVEF <50% and with evidence of cachexia, fatigue, or functional impairments.
LITHOS - AstraZeneca
The primary purpose of this study is to assess the benefits and safety of a budesonide and formoterol fumarate inhaler on both lung function and asthma health-related quality of life.
Primary inclusion criteria: Participants aged 12-80 years, with a history of physician-diagnosed asthma >6 months, who have been regularly using a stable daily ICS or an ICS/LABA regimen.
HERMES - NovoNordisk
The current study is to demonstrate the efficacy of ziltivekimab in reducing morbidity and mortality in patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.
Primary inclusion criteria: Adults aged 18+ with a clinical diagnosis of heart failure (NYHA Class II-IV), and LVEF > 40%.
E-Coli Vaccine Trial
Contact:
613-774-2420 ext. 6211
research@wdmh.on.ca
E-Coli is a very common bacteria and is the number one cause of Urinary Tract Infections (UTIs). Left untreated, and especially in older adults, this bacteria can progress further into the internal organs and bloodstream, leading to systemic bacterial infection. Once the bacteria travels into the bloodstream and internal organs, it requires the use of complex IV antibiotics to treat. However, E-Coli bacteria is becoming highly resistant to most commonly-used antibiotics. This antibiotic resistance can lead to treatment failure, increased hospitalization, morbidity, and mortality rates, and increased healthcare costs.
This study will assess the safety and efficacy of an E-Coli vaccine, to determine whether the vaccine will help to provide protection from urinary tract infections caused by E-Coli bacteria, and prevent the systemic bacterial infections that can occur.
Primary inclusion criteria: Adults 60+ with a history of UTI within the last 2 years.
|
GET INVOLVED:
If you would like to participate in any of our future research studies or would like any information on our current projects, please contact our research department at research@wdmh.on.ca.